Table 3 SLC6A3 polymorphisms and haplotypes by percent change in weight
From: SLC6A3and body mass index in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
| Â | Â | Â | Â | % Change in weight from age 20 to age 50 | |||||
|---|---|---|---|---|---|---|---|---|---|
|  |  |  |  | 5.1–15.0% (N = 806) vs. ≤ 5% (N = 515) | 15.1–25.0% (N = 524) vs. ≤ 5% (N = 515) | > 25% (N = 481) vs. ≤ 5% (N = 515) | |||
Polymorphism |  | N | G Freq (%) | OR‡ | (95% CI) | OR‡ | (95% CI) | OR‡ | (95% CI) |
SLC6A3 VNTR | *9 | 724 | 39.9 | 0.88 | (0.70, 1.13) | 0.92 | (0.71, 1.20) | 0.90 | (0.68, 1.18) |
| Â | 99 | 119 | 6.5 | 1.10 | (0.70, 1.73) | 0.70 | (0.41, 1.22) | 0.64 | (0.36, 1.14) |
Ex9-55A>G | AG | 711 | 39.0 | 1.16 | (0.91, 1.48) | 1.28 | (0.98, 1.67) | 1.14 | (0.87, 1.50) |
| Â | GG | 138 | 7.2 | 0.86 | (0.56, 1.34) | 0.96 | (0.60, 1.54) | 0.70 | (0.41, 1.20) |
Ex2+159C>T | CT | 188 | 10.8 | 1.02 | (0.70, 1.47) | 1.06 | (0.71, 1.57) | 0.87 | (0.56, 1.35) |
| Â | TT | 6 | 0.4 | 0.76 | (0.14, 4.17) | 0.82 | (0.13, 5.09) | 0.46 | (0.08, 2.76) |
-3714G>T | GT | 194 | 11.1 | 1.01 | (0.70, 1.45) | 1.17 | (0.80, 1.73) | 0.80 | (0.51, 1.24) |
| Â | TT | 8 | 0.5 | 0.74 | (0.15, 3.56) | 0.92 | (0.18, 4.78) | 0.48 | (0.08, 2.87) |
Haplotype†|  |  |  |  |  |  |  |  |  |
A-C-G-* | Â | 2153 | 50.9 | 1.00 | (reference) | 1.00 | (reference) | 1.00 | (reference) |
A-C-G-9 | Â | 596 | 14.1 | 0.92 | (0.72, 1.18) | 0.74 | (0.56, 0.98) | 0.70 | (0.52, 0.94) |
A-T-T-* | Â | 202 | 4.8 | 1.15 | (0.76, 1.73) | 1.23 | (0.79, 1.93) | 0.94 | (0.57, 1.53) |
G-C-G-* | Â | 592 | 14 | 1.05 | (0.82, 1.36) | 1.12 | (0.85, 1.47) | 0.91 | (0.68, 1.23) |
G-C-G-9 | Â | 456 | 10.8 | 1.07 | (0.81, 1.43) | 1.12 | (0.82, 1.53) | 0.96 | (0.69, 1.34) |